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Objective: Population-based cohort studies suggest an association between osteoarthritis (OA) and ce-
rebrovascular disease, yet the mechanisms underlying vascular comorbidities in OA remain unclear. The
purpose of this narrative review is to discuss the literature examining inflammation in OAwith a focus on
physiological mechanisms, and whether overlapping mechanisms exist in cerebrovascular dysfunction.
Method: A literature search was conducted in PubMed using combinations of search terms: osteoarthritis,
cerebrovascular (disease/dysfunction/risk), cardiovascular (disease/dysfunction/risk), aging/ageing, inflam-
mation, inflammatory mediators, cytokine, c-reactive protein, interleukin, advanced glycation end-products,
metabolic syndrome, reactive oxidative species, cognitive impairment, (vascular-related) dementia, small
cerebral vessel disease, endothelial function, bloodebrain barrier, gender/sex, hypertension, peripheral
vascular health, and physical activity. Reference lists of identified articles were also researched manually.
Results: Overlapping inflammatory factors that may contribute to onset and progression of both OA and
cerebrovascular dysfunction are presented. We describe oxidative mechanisms involving pro-
inflammatory cytokines and oxidative species, advanced glycation end-products, sex hormones, micro-
vascular dysfunction and osteoprotegerin, and their specific roles in potentially contributing to OA and
cerebrovascular dysfunction.
Conclusion: Synthesis of the current literature suggests future investigations may benefit from directly
testing cerebrovascular hemodynamics and cognitive function in individuals with or at risk of OA to
elucidate common physiological mechanisms.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Musculoskeletal and cardiovascular diseases (CVDs) together
contribute substantially to the global economic burden of illness1,
and may possess overlapping mechanisms in disease progression.
Individuals with osteoarthritis (OA), the most prevalent joint-
related disorder2, are prone to developing hypertension3, a risk
factor for cardiovascular and cerebrovascular disease (CeVD) onset.
While CVD is the leading cause of death for most living with OA4,
driven mainly by decreased mobility5,6, those with OA are also
more likely to experience stroke7. With a rise in the aging, obese,
and less active population, incidence and prevalence of OA8 and
vascular co-morbidities9 are likely to increase. These concerning
projections emphasize the need to understand the progression of
these disorders to inform preventative and therapeutic strategies.
The overlap in the prevalence of OA with vascular diseases also
raises the possibility of shared disease mechanisms (Fig. 1). In this
narrative review, we focus on shared mechanisms in OA and CeVD.
Pathophysiological mechanisms of OA and vascular diseases are
complex, suggesting that any potential interaction between OA and
cardiovascular pathology is likely multi-factorial. For example,
physical inactivity due to OA-attributed discomfort and pain may,
at least in part, explain the increased prevalence of CVD in hip and
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knee OA5, yet the association of symptomatic (but not asymptom-
atic) hand OA with cardiovascular events remains after accounting
for levels of physical activity10. However, additional factors for the
association between vascular co-morbidities and OA may exist11.
Chronically or intermittently-elevated levels of systemic
inflammation may be an additional link between OA and vascular
disease. The traditional consideration that OA represents a non-
inflammatory condition is now reconsidered with the view that
chronic, low-grade local inflammation underlies the OA process,
driven by several inflammatory mechanisms12,13. Local inflamma-
tion exists at the joint (e.g., synovitis and inflammatory mediators
in the synovial fluid); however, whether systemic inflammatory
mechanisms also exist remains controversial, but some evidence
exists. For example, chronic and low-grade inflammation occurs
with aging (i.e., “inflammaging”)14, and OA becomes more preva-
lent with age15. Independent of aging, blood immune composition
changes (affected sub-phenotypes of T and B-cells) occur in those
with OA which suggests a systemic change in inflammatory pro-
cesses accompanying OA16. The clinical significance of such
immunological shifts, however, is uncertain. Similarly, plasma
levels of prostaglandin E2 and 15-hydroxyeicosatetraenoic acid,
derivatives of the arachidonic acid cascade, were elevated in pa-
tients with symptomatic knee OA, and correspond with OA pro-
gression (i.e., joint space narrowing)17. These studies suggest that
Fig. 1. Schematic highlighting local and systemic mediators of, and shared risk factors for osteoarthritis (OA) and cerebrovascular dysfunction. The hip, knee and hand (most
prevalent sites for OA incidence) represent OA disease, and the brain highlights location for cerebrovascular dysfunction. Shared risk factors are indicated in the Venn diagram on
bottom.
B.K. Al-Khazraji et al. / Osteoarthritis and Cartilage 26 (2018) 462e470 463
several low-grade chronic inflammatory processes occurring
locally in joints affected by OA are also reflected systemically.
Several shared inflammatory mediators between OA and CVD
include inflammatory cytokines (e.g., interleukin-6)18,19, oxidative
pathways20,21, and C-reactive protein (CRP)22e24. Inflammation
leads to vascular endothelium dysfunction, where endothelial
dysfunction predicts cardiovascular event incidence25. Impaired
flow-mediated dilation responses seen in those with OA indicate
poor vascular endothelial function26, which may serve as an early
sign of peripheral vascular dysfunction. Endothelial function is also
integral to cerebrovascular health, with the endothelial cells
forming tight junctions in the bloodebrain barrier (BBB). Endo-
thelial dysfunction is involved in both cardiovascular (e.g., athero-
sclerosis and myocardial infarction) and CeVD (e.g., stroke)27.
Therefore, since endothelial dysfunction and the incidence of both
CVD and stroke are higher in those with OA7, cerebrovascular
dysfunction (i.e., when mechanisms for regulating cerebral blood
flow are compromised) may also be an under-recognized form of
vascular dysfunction in OA.
Cardiovascular and CeVD share several risk factors including
age, diet, physical activity, sex, hypertension28. Impaired cerebro-
vascular reactivity predicts stroke in those with carotid artery
disease29, and OA progression is associated with carotid artery
disease onset30. Moreover, while population-based cohort studies
suggest an association between OA and CeVD (Table I), whether or
not a causative relationship exists is unknown. As an essential step
in elucidating the association between OA and CVD/CeVD, this
narrative review will discuss the literature examining whether
inflammation, and specific physiological mechanisms in OA are
shared with cerebrovascular dysfunction.
What is cerebrovascular dysfunction?
Functional cerebral vessels ensure that brain tissue receives a
continuous blood supply. Functional cerebral vessels include intact:
1) BBB, 2) myogenic mechanism (i.e., reflex vasoreactivity), and 3)
functional hyperemia (i.e., increase in blood flow accompanying
tissue activity)31. Cerebral endothelial cells form tight junctions
which underlie an intact BBB, where endothelial dysfunction leads
to CeVD onset (e.g., stroke)27. The myogenic response reflects the
capacity of cerebrovascular smooth muscle cells to respond to local
changes in intravascular pressure, as a form of autoregulation, to
keep blood flow constant within the cerebral vessels. Functional
hyperemia is operationally-defined by cerebrovascular reactivity,
or respective changes in blood flow to endogenous and/or exoge-
nous vasoactive agents (i.e., dilators and/or constrictors)31. Both the
myogenic mechanism and functional hyperemia contribute to ce-
rebrovascular autoregulation, which describes the brain's ability to
maintain cerebral blood flow in the face of perfusion pressure
changes32. Thus, cerebrovascular dysfunction occurs when adap-
tive mechanisms for regulating cerebral blood flow are compro-
mised, potentially resulting in inadequate cerebral blood flow
distribution. Dysfunctional cerebrovascular autoregulation33 and
reactivity29 are both involved in predicting poor cerebrovascular
outcomes for those at risk.
Besides smoking, which seems to have a positive relationship
with cerebrovascular disorders34 and an inverse relationship with
OA progression35, several other risk factors and underlying mech-
anisms are shared between cerebrovascular dysfunction and OA
(discussed below).
Potential shared inflammatory mechanisms between OA and
cerebrovascular dysfunction
At the local tissue level, tissue damage in OA is explained, at
least in part, by an increase in various inflammatory mediators,
such as pro-inflammatory cytokines and Reactive Oxygen Species
(ROS)13. In this section, we will discuss some of the overlapping
inflammatory and oxidative mechanisms involved in local and/or
systemic progression of OA and cerebrovascular dysfunction
(Fig. 1).
LOX-1
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
is found on the surface of the vascular endothelium and is the re-
ceptor for oxidized low-density lipoprotein (oxLDL), a more reac-
tive form of low-density lipoproteins (LDL). LOX-1 receptor
activation by oxLDL binding causes altered production of nitric
oxide by the endothelium, in part via superoxide production36.
oxLDL binding to LOX-1 receptors on the endothelium leads to
intimal layer thickening and lipid deposition37.
Evidence of a systemic role
Through proteolytic cleavage, LOX-1 may release into the
bloodstream as soluble LOX-1, and act as a systemic biomarker for
early diagnosis of acute coronary syndrome38. In an age-and sex-
matched study (age 40e79 years), acute stroke patients showed
higher serum levels of LOX-1, indicating that soluble LOX-1 may
also act as a systemic biomarker for acute stroke39.
Evidence of a local role
Oxidized LDL (ox-LDL) binding to LOX-1 causes increased acti-
vation of nuclear factor-kappa B (NF-kB) signaling and production
of ROS in bovine articular chondrocytes40. This effect may be
mitigated partly by synovial cells, since ox-LDL injection into
mouse knee joints did not induce an inflammatory response41.
Nevertheless, using a murine model of post-traumatic OA, via
destabilization of the medial meniscus (DMM) experimental
model, Hashimoto et al. concluded that LOX-1 is critical in OA
progression, as LOX-1þ/þ mice had more knee joint damage (i.e.,
cartilage degeneration and osteophyte formation) compared to
LOX-1/ mice42. It is unclear from the above experiments whether
the observed effects of LOX-1 receptor are a result of variations in
LOX-1 receptor expression or changes in the ox-LDL ligand
concentration.
Adaptations in lipid metabolism may underlie OA progression,
as indicated by increased serum cholesterol levels and lipid depo-
sition within the joint during early OA43. Although serum LOX-1
levels are greater in stroke patients, further research is necessary
to determine whether LOX-1 is also higher in individuals before
stroke and whether this correlates with cerebrovascular dysfunc-
tion. Future work could determine whether heightened levels of
circulating lipids and/or LOX-1 receptor expression affect
Table I
Epidemiological studies highlighting vascular comorbidities (including cerebrovascular disease) in those with osteoarthritis
Author (year) Osteoarthritis patient sample Type of study Vascular-comorbidities event
Hsu (2017) Severe OA: knee or hip replacement required
Mild to Moderate OA: no surgery required
Retrospective population-based cohort Hemorrhagic or thrombotic stroke
Hawker (2014) Moderate to severe
Hip, knee
Population-based cohort Acute myocardial infarction, coronary revascularization,
heart failure, stroke or transient ischemic attack
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cerebrovascular function in those with OA and whether loss or
inhibition of LOX-1 has a protective effect on cerebrovascular out-
comes as it does in experimental OA.
hs-CRP
As part of the inflammatory process, hepatocytes and adipocytes
release C-reactive protein (CRP) via cytokine-regulated mecha-
nisms44. Increased plasma levels of CRP [measured through high-
sensitivity CRP (hs-CRP) immunoassays] introduce low-grade sys-
temic inflammation which threatens the functional integrity of the
vascular endothelial layer. Besides indicating systemic inflamma-
tion, CRP modulates innate immunity via complement binding and
fixation. Interestingly, CRP has also been shown to be a ligand of
LOX-1, although the effect of this interaction remains unclear45.
Evidence of a systemic role
CRP serum levels correlate with radiographic severity of OA46.
hs-CRP serum levels correlate with pain symptom severity (using
WOMAC pain scale) over a 5-year period47. CRP is also associated
with CVD progression, as seen in those with coronary artery dis-
ease, where the endothelial function is also compromised48. As
well, systemic hs-CRP levels remain elevated for as many as 28 days
following a stroke, at levels higher than hypertensive and normo-
tensive individuals49. CRP is also related to cognitive outcomes, as
Miralbell et al. showed that CRP levels were negatively correlated
with cognitive functions like verbal fluency performance50. Miral-
bell et al. also showed that CRP levels were associated with loss in
brain white matter integrity in individuals without a history of
symptomatic CVD51, which suggests CRP is associated with pre-
clinical changes in cerebral anatomy that may have an impact on
long-term cognitive outcomes. In another study, after adjusting for
age, gender, BMI, smoking status, and circulating lipids, higher
serum levels of IL-6 and CRP were associated with poorer physical
and cognitive performance and even predicted the risk of mortal-
ity52. Although the local role of CRP on human cerebrovasculature is
unknown, it is possible that levels of CRP could rise in patients with
OA and affect the endothelium and BBB.
Evidence of a local role
In response to injury, local inflammatory cells release cytokines,
like IL-6, into the bloodstream, and the liver responds by releasing
acute phase reactants such as CRP53. Higher levels of hs-CRP
(~2.5 mg/L) increase paracellular permeability in a mouse model
of adult-onset obesity54. These data suggest that both OA and CeVD
may share a common component of systemic inflammation. Future
studies should seek to test this question as a potential mechanism
mediating co-morbid effects of systemic inflammation between OA
and CeVD.
It is important to note that CRP is also often high in obese in-
dividuals55, and that metabolic syndrome (MetS; i.e., a combination
of obesity, hypertension, dyslipidemia, insulin resistance) is asso-
ciated with increased risk of knee OA. To explore whether CRP was
inherent to OA independent of confounding MetS components,
Engstr€om et al. found that the association of CRP levels with knee
OA incidence was attenuated after risk factor adjustments and
initial associations were largely due to body mass index56.
Interleukin-6 (IL-6)
Specific inflammatory mediators play a prominent role in OA
progression. As an example, synovial fluid cytokine levels of IL-6
and IL-8 were higher in patients with end-stage OA than a trau-
matic knee injury groupwithout OA, despite a similar need for knee
replacement surgery18.
Evidence of a systemic role
Higher serum cytokine levels of IL-6 and IL-857 and plasma
levels of IL-658 are found in those with OA. In the context of cere-
brovasculature, a 7 year-long observational study conducted in 803
Japanese participants with vascular risk factors, those with higher
circulating levels of IL-6 were more likely to develop dementia59.
Additionally, the association of IL-6 with incidental vascular-related
dementia remained significant despite multivariable analyses ac-
counting for other conventional risk factors (e.g., gene variants and
CRP levels)59.
Evidence of a local role
In an OA-induced (via DMM) mouse model, systemic IL-6
blockade alleviated OA cartilage lesions, and it was determined
that downstream signaling during IL-6 activation mediates the
catabolic effects of IL-6 on cartilage, namely via signal transducer
and activator of transcription-3 (Stat3) phosphorylation60. Simi-
larly, in hypoxic-ischemia brain injury in neonatal mice, selective
inhibition of the glycogen synthase kinase 3 isoform (i.e., GSK3ß)
was neuroprotective by reducing Stat3 phosphorylation which can,
in part, be attributed to the ability of GSK3ß inhibition in decreasing
IL-6 production61.
Recently, the term “vascular contributions to cognitive impair-
ment and dementia” (VCID) was used to explain the role of cere-
brovascular functionality on cognitive decline62. With these
findings, we speculate that the heightened IL-6 levels in those with
OA, and known vascular risk factors, may be one way in which
those with OA might be put at higher risk for developing dementia.
Together, these data provide evidence that IL-6 may have a role in
the progression of both OA and cerebrovascular dysfunction.
Further studies are required to investigate the role of IL-6 as a
candidate systemic biomarker of cerebrovascular-related cognitive
decline in OA.
Reactive oxygen species (ROS)
Increased ROS production can induce oxidative stress which
then impacts cellular activity. The production of ROS is increased
with ageing, hypertension, endothelial dysfunction, and vascular
inflammation63. Both cerebral vascular cells and chondrocytes have
the ability to produce ROS (see below), where excessive ROS pro-
duction leads to cerebral microvascular dysfunction and the pro-
motion of osteoarthritis, respectively. As an example, in the brain,
cerebral endothelial nitric oxide synthase can produce superoxide
anion (a member of the ROS family) that impairs the nitric oxide
signaling pathway64 underlying healthy vascular function. As well,
in cerebral small vessel disease, there is an increase in local ROS
production, primarily via NADPH oxidase activity65. In this section,
we discuss the local effects of ROS production at the cerebrovas-
cular level and during OA progression.
Evidence of a local role
With regards to OA progression, a higher mRNA level of NADPH
oxidase isoform was found in a rodent model of OA, where con-
sumption of alpha-lipoic acid (an ROS scavenger) provided chon-
droprotective effects via decreased NADPH oxidase production66. In
congruence with the OA rodent study, higher age-related levels of
plasma NADPH oxidase activity in humans with knee OA correlated
with greater cartilage degradation and KellgreneLawrence grade67.
As well, ROS activity was indicated by an accumulation of nitro-
tyrosine (a product formed after nitric oxide reacts with ROS) in
histological sections of knee and ankle articular cartilage samples
taken from human adults with OA68. ROS production also affects
BBB integrity and is implicated in several BBB diseases69, which
may result in ROS accumulation near the cerebral vessels and
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ultimately cause fatal neurological and/or cerebrovascular
dysfunction. As discussed, ROS production is a major cause of ce-
rebral small vessel disease which leads to the development of
subsequent “vasculo-cognitive” defects.
It is unknown whether the NADPH oxidase activity accompa-
nying OA progression is predictive of, or associated with, cerebro-
vascular dysfunction. Whether mechanisms that cause higher ROS
production in chondrocytes during OA are also implicated in ce-
rebrovascular dysfunction remain to be determined. As such, future
studies may want to investigate how ROS production pathways
implicated during hypercholesterolemia, or aging, may affect OA
progression and whether these pathways implicate cerebrovascu-
lar dysfunction.
Potential mechanisms related to shared risk factors between
OA and CeVD
Aging
Although OA becomes more prevalent with age, the mechanistic
processes responsible for onset and progression of OA remain
insufficiently understood. Aging is associated with increases in
catabolic factors and cytokines that increase ROS production and
oxidative stress, thereby promoting progression of OA70. As well,
elevated low-grade systemic inflammation detected in OA, also can
be observed with aging in general8. This phenomenon has been
coined “inflammaging”71. One theory regarding inflammation and
OA progressionwith aging considers the role of advanced glycation
end products (AGEs), which are produced in aging tissue, and
weaken cartilage by altering its mechanical properties12,72. AGE
receptors (RAGE) are present on chondrocytes73, and upon AGE-
binding, RAGE activation leads to increased production of pro-
inflammatory cytokines, specifically IL-6 and IL-8, thereby
increasing inflammation19. AGEs interfere with human BBB
permeability, and leads to the enhanced release of IL-6 and IL-874.
As described above, BBB integrity is imperative for intact cerebro-
vascular function.
Similar to RAGE activation during OA progression, RAGE gene
overexpression is present in vascular disease75. In the case of CeVD,
the polymorphism rs1035798 of the RAGE gene was associated
with increased risk of hemorrhagic stroke in those under the age of
5076. In a 9-year follow-up study, systemic serum levels of N
P
-
(carboxymethyl)lysine (CML), a robust AGEwhose circulating levels
are representative of overall AGE burden, were correlated with the
incidence of coronary heart disease and stroke77. Higher stroke-risk
individuals may also have greater levels of RAGE and AGE that could
weaken cartilage and lead to OA progression. Taken together, aging
may contribute to onset and/or progression of OA and cerebro-
vascular dysfunction through direct and/or indirect actions of
inflammaging, and specifically due to the role of AGEs. Further
prospective studies should focus on determining whether local
and/or systemic levels of AGEs in OA predict incidence of stroke.
Sex differences
According to the World Health Organization, women have a
higher lifetime risk of experiencing stroke, which suggests that
they are at a higher risk of developing cerebrovascular dysfunction,
as in most cases, cerebrovascular dysfunction precedes stroke29. In
The Framingham Osteoarthritis Study, the rate of knee OA inci-
dence was 1.7 times higher in elderly (~70 years) women than in
men, and the disease progression was also higher in women
(relative risk ¼ 1.4, compared to men)78.
Estrogen and its receptor subtypes are key players in the gender-
based disparity for both OA progression and stroke risk. Both
estrogen receptor subtypes, ERa and ERb, are co-expressed in brain
and bone tissues. OA prevalence increases with menopause79,80,
and the decrease in estrogen accompanying menopause is not only
shown to affect articular cartilage, but also subchondral bone,
synovium, periarticular muscles, and the articular capsule80. Simi-
larly, the cardio-protective role of estrogen is explained in part by
increased nitric oxide synthase production, angiogenesis, and
decreased ROS production79. Inflammatory insult presents greater
BBB disturbances in older female mice compared to young female
mice81. The role of sex hormones in BBB disruption was supported
by similar outcomes in ovariectomized young female mice, an ef-
fect that was reversible with estradiol replacement, where estradiol
protected the BBB via maintenance of key barrier features (e.g.,
paracellular permeability and tight junction integrity). The role of
NADPH in both small cerebral vessel disease and osteoarthritis (via
ROS production), considered alongside the fact that older women
are more likely to develop OA, suggests that post-menopausal
women are especially at a high-risk of CeVD due to increased ROS
production and potential loss of BBB integrity.
Shared mechanisms in progression of OA and vascular
dysfunction: the “chicken or egg”
Cardiovascular events are higher in OA than age-matched con-
trols82, especially inwomenwith OA affecting two or more joints83.
Specifically, those with OA are over twice as likely to develop
ischemic heart disease or heart failure84, and even after accounting
for cardiovascular risk factors, atherosclerosis is more prevalent in
women with knee and hand OA30. Potential associations between
OA and vascular comorbidities are outlined schematically, high-
lighting the potential relationship(s) between OA and cerebrovas-
cular dysfunction (Fig. 1). The proposed relationship(s) introduce(s)
an interesting “chicken or egg” thought on the directionality and/or
simultaneous progression of OA and vascular impairment. Here, we
suggest possible overlapping systemic and local vascular-related
mechanisms between OA and vascular dysfunction.
Systemic vascular mechanisms
Osteoprotegerin (OPG) is a key modifier of bone resorption (via
osteoclast regulation), and is also associated with vascular endo-
thelial function and is predictive of early atherosclerosis in coro-
nary artery disease patients85. As a circulating glycoprotein, OPG
acts to antagonize receptor activator nuclear factor kappa-B ligand
(RANKL), thereby affecting osteoclasts and preventing further bone
breakdown86. A higher level of OPG was also found in serum levels
of those with OA where levels were correlated with the
KellgreneLawrence scale for radiographic OA severity87. The role of
OPG in both atherosclerosis and bone remodeling suggests a
possible overlapping mechanism in the progression of OA and CVD.
These higher levels of OPG may serve to progress OA, and may
occur in tandem (or before/after) development of dysfunctional
vascular remodeling.
Local (Joint) vascular mechanisms
Limited data exist which consider the potential role of vascular
dysfunction in the progression of OA. While it is suggested that
local vascular pathology potentiates osteoarthritis progression via
subchondral bone ischemia88, the systemic macrovascular changes
present during CVD may also contribute to OA progression. Arte-
riosclerosis may influence the fate of bone health, where vascular
calcificationmay share overlappingmechanismswith skeletal bone
remodeling89.
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Potential cognitive outcomes in OA from the perspective of
cerebrovascular dysfunction
Cerebrovascular outcomes in those with OA may lead to
neurological damage, which may include, but is not limited to,
changes in cognition, gait, or autonomic control. In most cases,
cerebral microvascular dysfunction is the leading cause of cerebral
small vessel disease and ultimately leads to impaired perfusion
within the brain that is followed by changes in cognitive func-
tion90. Similarly, in a transgenic mouse model of Alzheimer's
disease, mice that were induced with OA (via viral injection into
knees) presented with greater Aß plaques and neuroinflammation
than those without OA, which suggest that peripheral inflamma-
tion may also be linked with Alzheimer's disease pathology91.
Cerebrovascular impairment can be assessed through character-
istic changes in this disease such as white matter hyperintensities,
brain atrophy, and small hemorrhaging92. Those with OA who
have undergone joint replacements have greater volume of white
matter hyperintensities, despite a lack of history of cardiac or
cerebrovascular events93. It is important to note that myocardial
infarction94 and stroke95 incidences are higher with major surgery
such as hip and/or knee replacement; thus, the effect of surgery
need to be assessed as a potential confounder when determining
white matter hyperintensities in these patients. Future OA studies
should investigate the presence of subclinical cerebral microvas-
cular damage and whether there is an association between cere-
bral microvascular damage and cognitive outcomes in these
patients.
Radiographic knee OA severity correlates negatively with
mobility, as indicated by a negative correlation between a higher
score on the KellgreneLawrence OA severity grading scale and
physical performance96. In a systematic assessment of gait in older
adults with mild cognitive impairment syndromes, velocity, stride
length, cadence values were lower in the cognitively-impaired
group97, suggesting that early cognitive decline may affect phys-
ical function. As summarized in a study looking at pain and
decreased cognition in older adults with OA, pain may influence
cognition, which then, in turn, may affect physical function98.
Decreased performance on executive function tests corresponded
with slower gait speed and stair climbing, and after adjusting for
performance scores on executive function testing, pain scores were
no longer correlated with physical test scores. Together, these
studies highlight the importance of OA-associated cognitive
decline, as cognitive ability may affect mobility and independence
in OA patients.
Summary
This narrative review presents a synthesis of studies, suggesting
that cerebrovascular dysfunctionmay be present in OA patients and
may underlie the observed increased risk of stroke in those with
OA. The shift from describing OA as a joint-centric disease in the
literature has opened discussion on underlying mechanisms of OA
progression and affiliated co-morbidities. The well-documented
association of OA with increased CVD, cognitive impairment,
brain white matter hyperintensities, increased systemic inflam-
mation, together create the ideal milieu for the onset of cerebro-
vascular dysfunction.
Perspective and future research
We highlighted the potential relationships between OA and
cerebrovascular dysfunction (Fig. 2). Future studies should aim to
confirm and determine if: 1) mechanisms are common to both
diseases, 2) OA-related inflammatory mechanisms directly increase
the risk of vascular dysfunction, 3) if vascular dysfunction leads to
the OA progression, or 4) if an external driver (e.g., metabolic
syndrome) promotes parallel disease progression. Future in-
vestigations may quantify parameters grounded in cognitive, he-
modynamic, and cellular data. Building on the current cross-
sectional correlational studies, future studies should focus on pro-
spective studies designed to delineate whether progression of both
diseases occurs in tandem, or whether a (bi-)directional relation-
ship exists between OA and cerebrovascular health outcomes.
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Fig. 2. Simplified schematic describing the proposed relationship between osteoarthritis and cerebrovascular dysfunction. Cmap© software (Institute for Human and Machine
Cognition, FL, USA) was used to create the schematic. Panel A: Osteoarthritis (OA) effects on vascular dysfunction (i.e., cardiovascular and cerebrovascular function) may in part be
explained via physical inactivity. Panel B: Inflammatory processes both drive and are driven by OA (bi-directionality indicated by double headed arrow). Inflammation promotes
vascular dysfunction independent of OA, and vascular dysfunction exacerbates OA. Panel C: Combining Panel A with Panel B, OA not only reduces the capacity to perform vasculo-
protective physical activity, but also progresses vascular dysfunction via inflammation. The role of inflammation on vascular function, together with the observed cardiovascular
complications associated with OA (black dashed line), suggest the hypothesis (red dashed line) that OA is also associated with cerebrovascular dysfunction. Panel D: Inflammation
drives the independent progression of OA and vascular dysfunction, and no causal or associative relationship exists between OA and vascular dysfunction.
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